Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

23 Mar 2009 07:00

RNS Number : 2116P
ViaLogy PLC
23 March 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY") 

VIALOGY TECHNOLOGY DELIVERS LARGE OIL FIND

 

LONDONMarch 23rd, 2009 - ViaLogy PLC (LSE: VIY). ViaLogy announces today that its QuantumRD™ oil exploration technology and service has been credited with locating a major new oil deposit on the Galba Prospect in South Central Texas. The success marks the operational and commercial validation of ViaLogy's software-based seismic interpretation service for oil and gas reservoir discovery and characterization. The technology accurately predicted the size, location and porosity of three reservoirs. 

The successful drilling effort and oil strike based on the ViaLogy analysis located reservoirs at increasing depths estimated to contain a total of over 2 million barrels of recoverable reserves. ViaLogy's contract with Atascosa Exploration LLC, of San AntonioTexas, for the Galba Prospect foresees multiple wells on the lease, now determined to be 4 or 5, targeted at the three reservoirs and positioned by ViaLogy. The first well, just completed, has located a reservoir with an estimated oil deposit which will produce 153,000 barrels of crude oil (i.e. 35% primary recovery based on an overall actual volume of 460,000 barrels). Atascosa plans extractions of 50% of the recoverable reserves in first three years. Under its contract with Atascosa, ViaLogy will receive a 5% Back-In-After-Payout (BIAPO) working interest. This means that after costs ViaLogy will receive over $300K during the life of this first well (assuming oil price at $40 per barrel). Galba Prospect production will begin immediately. For the entire field, ViaLogy could receive 5% of the 2 million barrels over the lifetime of the field's wells which, assuming an average $40 oil price, would produce around $4 million.

ViaLogy's role in the Galba Prospect project included the design and acquisition of new, high-resolution 3D seismic survey data, integrated geoseismic and geological assessment, and positioning of the drill site. ViaLogy collaborated closely with Atascosa's geology and production team. Oil was found at the depth and with the porosity ViaLogy predicted in the Upper Wilcox formation, and all other parameters conformed to ViaLogy's analysis and its determination of coordinates for the drilling site.

ViaLogy believes that its geoseismic interpretation technology will address a problem faced by the oil industry worldwide - to avoid drilling dry holes. In Texas, only four out of 10 exploratory wells, including those drilled with the aid of seismic, find oil or gas in economically producible quantities. Abortive attempts are costly. According to US Dept. of Energy (DOE) Energy Information Administration (EIA) statistics, the 2006 average cost for drilling an on-shore dry hole in the US was over $450,000. The success of the Galba Project reinforces QuantumRD's value proposition for locating oil reservoirs while lowering the probability of dry holes, and thus reducing the overall cost of exploration. 

Working with Atascosa, ViaLogy plans to market the QuantumRD technology and service initially to US independent exploration companies. QuantumRD is a computational technology based on ViaLogy's patented Quantum Resonance Interferometry (QRI™), an active signal processing technique capable of significantly increasing the signal to noise ratio of seismic data and improving its value.

Commenting on the Galba Prospect find, Atascosa's Chief Executive, John Mullins, said: "We're very pleased with the success of this well. We have increased our lease positions at the prospect, and are planning to further grow our collaboration with ViaLogy on Galba and other prospects. Our geology team has been working with the ViaLogy scientists for some months now, and we're highly impressed with the technology behind QuantumRD. The accuracy of the results is remarkable and the payoff is reducing the risk of dry holes."

He added, "The quality of the information relating to the size and content of the reservoirs enables us to position the wells to extract the maximum amount of hydrocarbons."

ViaLogy's CEO, Robert W. Dean, commented: "Our success in Texas validates QuantumRD, and is a key step in building a services business in the oil and gas industry. We have a potentially global product, but initially we intend to focus our sales efforts for our oil detection technology and services on US-based independent exploration companies. Going forward, we expect it will be attractive to established seismic data companies, oil field services companies, and the oil majors."

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Atascosa Exploration LLC   John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor (Seymour Pierce)   Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC 

Sebastian Wykeham, St. Helen's Capital - +44 (0) 7628 5582 

About ViaLogy: Network Centric Signal Processing   ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPUURWWUPBGGU
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.